Drug Type Small molecule drug |
Synonyms HL 085, HL-085, HL085 + [1] |
Target |
Mechanism MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization Shanghai Kechow Pharma, Inc.Startup |
Active Organization Shanghai Kechow Pharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (12 Mar 2024), |
RegulationConditional marketing approval (CN), Priority Review (CN) |
Molecular FormulaC16H12F2IN3O3S |
InChIKeyUFZJUVFSSINETF-UHFFFAOYSA-N |
CAS Registry1801756-06-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
NRAS Mutant Melanoma | CN | Shanghai Kechow Pharma, Inc.Startup | 12 Mar 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600E mutant Colorectal Cancer | Phase 3 | CN | Shanghai Kechow Pharma, Inc.Startup | 16 Oct 2023 |
BRAF V600E mutant Non-small Cell Lung Cancer | Phase 2 | - | Shanghai Kechow Pharma, Inc.Startup | 24 Sep 2023 |
Metastatic Colorectal Carcinoma | Phase 2 | CN | Shanghai Kechow Pharma, Inc.Startup | 24 Feb 2022 |
NF1 mutant Plexiform Neurofibroma | Phase 2 | CN | Shanghai Kechow Pharma, Inc.Startup | 01 Nov 2021 |
Neurofibromatosis 1 | Phase 2 | CN | Shanghai Kechow Pharma, Inc.Startup | 18 Oct 2021 |
BRAF mutation positive Melanoma | Phase 2 | CN | Shanghai Kechow Pharma, Inc.Startup | 23 Sep 2021 |
KRAS mutant Non-small Cell Lung Cancer | Phase 1 | CN | Shanghai Kechow Pharma, Inc.Startup | 21 May 2020 |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | Shanghai Kechow Pharma, Inc.Startup | 01 Jul 2018 |
BRAF Mutation Non-small Cell Lung Cancer | IND Approval | CN | Shanghai Kechow Pharma, Inc.Startup | 26 Jun 2023 |
RAS/RAF mutation Solid Tumors | Preclinical | CN | Shanghai Kechow Pharma, Inc.Startup | 21 Sep 2023 |
NCT03781219 (Pubmed) Manual | Phase 1 | BRAF mutation Solid Tumors BRAF V600 | 72 | (NSCLC) | fvfzakhgjb(wwyianjkeg) = All 72 patients had treatment-related adverse events (TRAEs) smiwazfuxf (ixagdkuchg ) View more | Positive | 12 Jun 2024 |
(RP2D) | |||||||
NCT05263453 (ASCO2024) Manual | Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600-mutant | 17 | tqyqfancnr(irovalhbrq) = kpgrfhaulp qvafmlsdvp (mhqngyncjq, 44.0 - 89.7) View more | Positive | 24 May 2024 | |
(pre-treated pts) | tqyqfancnr(irovalhbrq) = irlgbbewsn qvafmlsdvp (mhqngyncjq, 46.2 - 95.0) View more | ||||||
Phase 2 | 100 | rabgutcsin(ceesbcbunr) = jowzvjwpwd gaaiwodukp (swztdlleym, 26.3% - 46.3%) View more | Positive | 24 May 2024 | |||
NCT03781219 (ESMO2023) Manual | Phase 1 | Advanced Malignant Solid Neoplasm BRAF V600 mutation | 72 | axeckblqqu(oueoluoyih) = The most common AE were CK elevation, anemia and rash which were predominantly grade 1/2. vyvqfjwfxn (zwmhissrdu ) | Positive | 23 Oct 2023 | |
(NSCLC) | |||||||
NCT05217303 (ASCO2023) Manual | Phase 2 | NRAS Mutant Melanoma NRAS Mutation | 100 | rsolojmcbp(qaufbmonox) = flmxkntitc eaviaaddfj (iasiljkjkb, 25.3 - 45.2) View more | Positive | 26 May 2023 | |
Phase 1 | 42 | ieeagpnndk(lkyfhgrbfj) = lpchrmadfx nfmbhmncrs (ycovvibskh ) View more | - | 04 Jan 2023 | |||
Phase 1/2 | 33 | dgbfsniopl(zndpvxirwe) = the most common drug-related AEs were aspartate aminotransferase hglannswgw (xfugmfczwj ) View more | Positive | 25 May 2020 |